Clinical trials: Persistent Atrial Fibrillation
Atrial Fibrillation, Persistent Common Pulmonary Vein
Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
The investigators studied the effects of adenosine on the reconnection rate after successful pulmonary veins isolation by radiofrequency catheter ablation in patients with drug-resistant atrial fibrillation
- Trial name
- APPLE (NCT01932112)
- Testing
- Adenosine arm
- Where
- South Korea
- Volunteers
- 378 people
- Sponsor
- Yong Seog Oh
Atrial Fibrillation, Paroxysmal Atrial Fibrillation
Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation
The purpose of Part 1 of this study is to determine the maximally tolerated dose of OPC-108459 in patients with paroxysmal and persistent atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
- Trial name
- CADENCE 215 (NCT01483183)
- Testing
- OPC-108459
- Where
- 25 sites in United States, Germany and 4 more
- Volunteers
- 40 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Persistent Atrial Fibrillation
Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Dose-ranging Phase II study testing the efficacy and safety of 3 doses of Ranolazine (low, intermediate and high, given BID) versus placebo in maintaining sinus rhythm after successful electrical cardioversion in patients with…
- Trial name
- RAFFAELLO (NCT01534962)
- Testing
- Ranolazine
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 241 people
- Sponsor
- Menarini Group
Persistent or Permanent Non-valvular Atrial Fibrillation
Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)
The purpose of this study is to assess the safety and tolerability of AZD0837 in patients with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for up to 3 months.
- Trial name
- NCT00623779
- Testing
- AZD0837, Aspirin
- Where
- 38 sites in Denmark, Norway and 4 more
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Persistent or Permanent Nonvalvular Atrial Fibrillation
Long-term Safety in Atrial Fibrillation Patients
The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and…
- Trial name
- NCT00645853
- Testing
- AZD0837, VKA INR 2-3
- Volunteers
- 523 people
- Sponsor
- AstraZeneca